Zika AG129 Mouse Model

Zika Virus (ZIKV) is a mosquito-borne flavirus associated with the recent outbreak of febrile disease across the Americas. Zika infection causes Zika fever and infection during pregnancy is hypothesized to cause micocephaly in neonates. The IFN α/β and IFN γ receptor deficient AG129 mouse model using ZIKV FSS13025 strain is based on previously described model (Rossi, et al., 2016). AG129 mice aged 6-8 week challenged with FSS13025 strain have a mean time to death of 11-12 days post infection.

This is a biologically relevant model for studying ZIKV infection that does not rely on intracerebral inoculation and it has the following advantages:

  • Lethal and/or non-lethal ZIKV infection model
  • No need for mouse-adapted ZIKV strains
  • Consistent symptoms associated with disease development
  • Well suited to screen antiviral compounds and vaccine candidate efficacy

Zika

Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

Alpha (UK) – B. 1.1.7 / 501Y.V1

amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

Beta (South Africa) – B.1.351

amino acid mutations: K417N, E484K, N501Y, D614G, A701V

Gamma (Brazil) – P.1

amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Epsilon (Ca, USA) B.1.427

amino acid mutations: L452R, D614G

SARS-CoV-2 Parental Strain Wild Type (Wuhan)
SARS-CoV-2 D614G Variant

amino acid mutations: D614G

Epsilon (Ca, USA) B.1.429

amino acid mutations: S13I, W152C, L452R, D614G

SARS-CoV-2 Delta Variant

amino acid mutations: L452R, E484Q